A Cell World Model
to End“Trial and Error”in the Life Sciences.
Technology & Services
Concept
AI that Understands"the World of Cells"and Predicts What Comes Next
Sekai Biotech is developing a Cell World Model that integrates AI with automated experimentation in a continuous learning loop. By predicting and controlling cellular state transitions, we aim to accelerate drug discovery, improve toxicity assessment, and advance disease model development.
Solution
Forward Prediction andInverse Designare Transforming Exploration in the Life Sciences
The Cell World Model supports both forward prediction—from intervention to outcome—and inverse design—from a target state to an optimal intervention. Together, these capabilities enable systematic, bidirectional exploration beyond conventional trial and error.
Technology
An Integrated,Closed-LoopPlatform for Autonomous Experimentation
Rather than treating AI models and laboratory systems as separate components, we integrate them into a unified closed loop. AI generates hypotheses and designs experiments; automated laboratory systems execute them; and the resulting data are analyzed to determine the next experiment. By running this cycle autonomously and continuously, the platform refines the world model and improves its experimental strategy through reinforcement learning.
About Us
Sekai Biotech is developing a Cell World Model that integrates AI with automated experimentation in a continuous learning loop. By predicting and controlling cellular state transitions, we aim to accelerate drug discovery, improve toxicity assessment, and advance disease model development.
Company Profile
Company Name
Sekai Biotech, Inc.
Business activities
Development of disease-state and toxicity assessment models using the Cell World Model
Established
May 25, 2026
Representative Director
Takayoshi Kawakami
Major Shareholder
Advanced Technology Acceleration Corporation (ATAC)
Team
Representative Director
Takayoshi Kawakami
After working at a trading company and GE, Kawakami joined Industrial Growth Platform, Inc. (IGPI). He has led engagements in advanced-technology commercialization, startup support, industry–academia collaboration, AI and digital transformation, new business development, and organizational and human capital strategy.
Director and Founder
Jun Seita
After clinical training in cardiovascular surgery, Seita earned a Ph.D. in medicine through stem cell research.
At Stanford University, he conducted interdisciplinary research integrating cell biology, data science, and machine learning.
Since 2016, he has conducted research at RIKEN on applications of deep learning to medicine and biology.
Executive Officer
Yasushi Tsuchida
After graduating from Tohoku University School of Medicine and obtaining his medical license, Tsuchida joined Industrial Growth Platform, Inc. (IGPI), where he led strategy development and R&D investment support for biologics companies. In 2022, he joined Advanced Technology Acceleration Corporation (ATAC), where he has led the commercialization of drug-discovery assets originating in academia.
Executive Officer
Masatoshi Mikami
After working in tax services at a tax accounting firm, Mikami gained broad experience at a company listed on the Tokyo Stock Exchange’s Mothers market, including IPO preparation, accounting and finance, tax, and corporate disclosure. He later joined IGPI, where he has overseen group-wide accounting, finance, and tax matters, including matters related to Japan’s group tax regime. As part of IGPI’s portfolio support activities, he has also assisted numerous startups in establishing and operating their accounting and tax functions.